TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03902340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiTENS
Description: ActiTENS is a rechargeable box, weighing 64g attached by Velcro to an adhesive support, which can be positioned on the skin at any position chosen by the patient. The patient will use the programme (P4) prescribed by his doctor and will regulate the intensity of stimulation using an application downloaded to his smartphone which will communicate with the box via Bluetooth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Level 2 Analgesic Treatments
Description: There are 4 level 2 oral analgesic treatments indicated for chronic nociceptive pain of moderate to severe intensity (between 4 and 7 on a simple numerical scale of 11 points) (12):~* Tramadol immediate release formulation (IR, one intake every 6 hours) or prolonged release formulation (PR, one intake every 12 hours); maximum posology 400mg/24h.~* Dihydrocodeine: 60mg every 12 hours; maximum posology 120mg/24h.~* Combination of paracetamol and codeine in a fixed combination every 6 hours; maximum posology of codeine: 300mg/24h.~* Combination of paracetamol and tramadol in a fixed combination; maximum posology of tramadol: 8 tablets/24h ie 300mg/24h.
Study: NCT03965117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is \> 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
Study: NCT01924234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study: NCT03059992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Experimental Study Drug
Study: NCT02449044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Once Daily
Study: NCT04323735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Culturelle 10 Billion CFU Capsule
Description: LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Culturelle 10 Billion CFU Capsule
Description: LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group.
Study: NCT06697613

Intervention type: PROCEDURE
Intervention: Hyperthermic intraperitoneal chemotherapy
Description: Patients diagnosed with FIGO Stage 3 or stage 4 ovarian cancer received hyperthermic intraperitoneal chemotherapy with cisplatin following cytoreductive surgery including primary debulking surgery, interval debulking surgery and secondary debulking surgery.
Study: NCT02608086

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducation
Description: Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid
Description: Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?.
Study: NCT04928131

Intervention type: OTHER
Intervention: No intervention - retrospective observational cohort study

Intervention type: OTHER
Intervention: No intervention - retrospective observational cohort study

Intervention type: OTHER
Intervention: No intervention - retrospective observational cohort study
Study: NCT04254250

Intervention type: DIAGNOSTIC_TEST
Intervention: Preoperative risk estimation of disc herniation recurrence
Description: Risk estimation of disc herniation recurrence will be evaluated preoperatively, depend on the risk significance each patient will be assigned to one of two groups - with high risk and low risk. Then each patient will undergo conventional one-level microdiscectomy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Preoperative risk estimation of disc herniation recurrence
Description: Risk estimation of disc herniation recurrence will be evaluated preoperatively, depend on the risk significance each patient will be assigned to one of two groups - with high risk and low risk. Then each patient will undergo conventional one-level microdiscectomy.
Study: NCT01994005

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook
Description: Facebook page with contraception information used for counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pamphlet
Description: Contraceptive knowledge pamphlets
Study: NCT02124980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Line
Study: NCT02981160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
Study: NCT03074448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquanet
Description: Aquanet bowel cleansing devices
Study: NCT01461616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection
Study: NCT01316497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: RIPC was performed by applying a blood pressure cuff around the child's leg. The cuff was inflated to 40 mmHg above the systolic pressure in 4 cycles of 5 minutes. Every cycle of ischemia was followed by 5 minutes of reperfusion. The first RIPC cycle started after anesthesia induction when invasive arterial blood pressure was monitored. Appropriate cuff size was used choosing between four sizes. For reproducibility RIPC was performed on the right leg with only a few exceptions, when the leg was used for invasive catheters.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The cuff was applied on the leg without inflation in the control group.
Study: NCT04660968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic health behaviour change intervention
Description: The dyadic behaviour change intervention adopts a dyadic coping perspective wherein appraisal of shared responsibility, agreement on tasks, and collaboration are fostered throughout the intervention. The intervention will target four behaviour goals: reducing overall caloric intake, substituting empty calorie foods with healthier alternatives, reducing sedentary behaviour, and increasing physical activity. The specific behavioural change strategies will include motivational interviewing, self-monitoring, goal setting, stimulus control, problem solving, and relapse prevention. Each session will also include a short education component on healthy eating to improve participants' adherence to the updated Canada's Food Guide. Participants will have access to web-based exercise training sessions. Intervention sessions will be delivered online.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dyadic nutrition counselling intervention
Description: The couples-based education nutrition intervention will provide extensive information on healthy eating. However, it will not include any behavioural change principles. Topics will be based on Dietitians of Canada's Practice-based Evidence in Nutrition (PEN) discussions in the database that focus on healthy eating for older adults. The topics covered will include increasing fruits and vegetables, hidden (empty) calories, how to read food labels, portion control, reducing salt and saturated fat, plant-based proteins, and eating for healthy bones. Participants in this group will also be told to increase their levels of physical activity to 150 minutes of moderate to vigorous physical activity per week, as per the Canadian Guidelines. Participants will have access to web-based exercise training sessions. However, physical activity will not be discussed explicitly during the intervention. Intervention sessions will be delivered online.
Study: NCT00542945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD
Description: Implantation of an ICD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment
Description: ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
Study: NCT03244592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 200 mg/day
Study: NCT03074448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate
Description: Sodium Picosulfate solution (Picoprep)
Study: NCT02151500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Health Interview
Description: A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
Study: NCT00573326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 200 mg p.o. once a day for 6 months
Study: NCT04056130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral
Study: NCT03671759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start: On Caffeine
Description: In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start: Off Caffeine
Description: In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
Study: NCT03059563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
Study: NCT03321240

Intervention type: PROCEDURE
Intervention: visual and quantitative SEEG signal analysis
Description: signal SEEG analysis

Intervention type: PROCEDURE
Intervention: Resective epilepsy surgery procedure
Description: Surgical removal of the epileptogenic brain area

Intervention type: PROCEDURE
Intervention: Resective epilepsy surgery procedure
Description: Surgical removal of the epileptogenic brain area
Study: NCT01505491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40mg adalimumab single s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI695501
Description: BI 695501 single s.c injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40mg adalimumab single s.c. injection
Study: NCT02230124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRE
Study: NCT00227279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK Grass tablet
Description: Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALK Grass tablet
Description: Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
Study: NCT03483688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-directed CAR-T cells
Description: CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
Study: NCT03747016

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-energy digestible food E2
Description: The women undergoing Cesarean section are given high energy digestible food 300ml before surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose injection G2
Description: The women undergoing Cesarean section are given glucose injection 300ml before surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: normal saline N2
Description: The women undergoing Cesarean section are given normal saline 300ml before surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-energy digestible food E1
Description: The women in delivery room are given high energy digestible food 300ml.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose injection G1
Description: The women in delivery room are given glucose injection 300ml.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: normal saline N1
Description: The women in delivery room are given normal saline 300ml.
Study: NCT04673409

Intervention type: DIAGNOSTIC_TEST
Intervention: Novel Cardiac MRI sequences
Description: Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.

Intervention type: DIAGNOSTIC_TEST
Intervention: Novel Cardiac MRI sequences
Description: Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.
Study: NCT02823262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Cancer Treatment Decision Aid for women 70+
Description: We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT01109901

Intervention type: PROCEDURE
Group type: OTHER
Intervention: anterior subcutaneous transposition
Description: transposition of ulnar nerve into subcutaneous bed

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior submuscular transposition
Description: transposition of ulnar nerve into muscular tissue
Study: NCT01414088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline 0,9 mg/ml
Description: infusion, 23 ml/kg, during 50 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline 2,9 mg/ml
Description: infusion, 7 ml/kg, during 50 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glucose 5%
Description: infusion, 23 ml/kg, during 50 minutes
Study: NCT03005847

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented papaya preparation
Description: dietary supplementation with fermented papaya preparation
Study: NCT04215354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic field
Description: Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic field
Description: Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Wii Fit plus machine which required balance board . It is a video game console designed by Nintendo 2009
Study: NCT01180140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seamguard
Description: GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
Study: NCT03430882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT00084422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lestaurtinib
Description: Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
Study: NCT03120390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo AE

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo AE

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo RE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Receive Polar heart rate monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Receive Polar heart rate monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies